Patent 11981967 was granted and assigned to Sangamo Therapeutics on May, 2024 by the United States Patent and Trademark Office.
The present disclosure provides methods and compositions to develop AAV capsids with a desired characteristic compared to a natural AAV serotype. These capsids are useful, for example, for the delivery of genome engineering molecules and gene therapy molecules for the treatment of a subject in need thereof.